Evidence map›Paper›PMID 41744756›Full record

ArticleCells2026

Rapid Drug Sensitivity Profiling via a Novel High-Success-Rate Culture Method for Patient-Derived Pancreatic Cancer: An Exploratory Preclinical Platform for Advancing Clinical Applications and Drug Development.

Yu Kato, Naoki Yamamoto, Yuichiro Uchida, Noriko Hiramatsu, Takato Ozeki, Yukari Minobe, Yukika Hasegawa, Sho Kawabe, Hikaru Yabuuchi, Seiji Yamada and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yu KatoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0002-4337-6775
Naoki YamamotoCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0002-9659-3204
Yuichiro UchidaDepartment of Surgery, School of Medicine, Fujita Health University, Aichi 470-1192, Japan.
Noriko HiramatsuOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Takato OzekiCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Yukari MinobeCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Yukika HasegawaCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Sho KawabeCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Hikaru YabuuchiCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Seiji YamadaOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Yuko HataOpen Facility Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Eiji SugiharaOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0002-3233-1045
Tetsuya TakimotoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0009-0009-3008-8078
Kuniaki SaitoCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.
Takeshi TakaharaDepartment of Surgery, School of Medicine, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0003-4800-955X
Koichi SudaDepartment of Surgery, School of Medicine, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0002-0423-1565
Osamu NaganoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0002-7630-142X
Hideyuki SayaOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Aichi 470-1192, Japan.ORCID 0000-0001-6610-1902

Funding

JST Program for co-creating startup ecosystem, Tokai Network for Global Leading Innovation (Tongali) JPMJSF2314JST Program for co-creating startup ecosystem, Tokai Network for Global Leading Innovation (Tongali) JPMJST2183
6 · The paper itself

Abstract

Pancreatic cancer is a highly intractable malignancy that necessitates personalized treatment strategies. Conventional patient-derived models, such as three-dimensional organoids, are often limited by intellectual property constraints and high costs. In this study, we developed an affordable adherent culture system for patient-derived pancreatic cancer cells using a proprietary medium and laminin-coated dishes. Primary cultures were successfully established from 28 patients with pancreatic ductal adenocarcinoma, exceeding a 90% success rate. Validation of eight samples confirmed maintenance of epithelial cell adhesion molecule expression and preservation of oncogenic

Indexed as

drug sensitivity assayfibroblast activation proteinfunctional precision medicineKRAS mutationpancreatic ductal adenocarcinomapatient-derived cellsprimary new culture method

Identifiers

PMID41744756
PMCPMC12939418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.